Anyone who has ever taken a high-school science class has almost certainly been introduced to mitochondria as “the powerhouse of the cell, where energy is produced in the form of ATP.” MitoGenetics LLC believes it has identified a substance that can potentially fix things that start to break down in mitochondria as human cells age, and thereby restore normal cell function to reverse, or possibly even prevent, a great many diseases.
[MitoGenetics LLC]
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
Chief medical officer Eliav Barr, responsible for overseeing clinical development, talked to Scrip in an interview at Merck’s headquarters about the company’s pipeline diversification.
Already a frontrunner in developing the KRAS G12D inhibitor class, analysts think Revolution Medicines could seal its leadership by combining zoldonrasib with other agents in its portfolio.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
